Clues to quality of journals
Open Access Policy of Helmholtz Association 2016
CC Licencences
Publication Metrics
Home
Deutsch
New EVA Application
Advanced Search
Browse by ...
Publication overview
Statistics (last 5 years)
OA Publications
Submit Publication
Import publication from...
Report missing publication
Contact persons
Help
Text
Endnote (RIS)
BibTeX
Publ. Version/Full Text Volltext
DOI
PMC
 |
Open Access Gold |
as soon as is submitted to ZB.
Next-generation personalized drug discovery: The tripeptide GHK hits center stage in chronic obstructive pulmonary disease.
Genome Med. 4:70 (2012)
ABSTRACT: Chronic lung diseases (CLDs), including chronic obstructive pulmonary disease (COPD), are the second leading cause of death worldwide. The first report of database-driven drug discovery in carefully phenotyped COPD specimens has now been published in Genome Medicine, combining gene expression data in defined emphysematous areas with connectivity-map-based compound discovery. This joint effort may lead the way to novel and potentially more efficient concepts of personalized drug discovery for COPD in particular, and CLD in general.See research article http://genomemedicine.com/content/4/8/67/abstract.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
0.000
0.719
6
8
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Pathogenesis
Language
english
Publication Year
2012
HGF-reported in Year
0
ISSN (print) / ISBN
1756-994X
e-ISSN
1756-994X
Journal
Genome Medicine
Quellenangaben
Volume: 4,
Issue: 8,
Article Number: 70
Publisher
BioMed Central
Reviewing status
Peer reviewed
Institute(s)
Institute of Lung Health and Immunity (LHI)
POF-Topic(s)
30202 - Environmental Health
Research field(s)
Lung Research
PSP Element(s)
G-501600-004
G-501600-001
G-501600-001
PubMed ID
22999295
DOI
10.1186/gm371
WOS ID
WOS:000314575900001
Erfassungsdatum
2012-11-29